lifestyle.tvshowauditions.info

Author: Nxera Pharma

Notice of Issuance of New Shares in Connection with the Introduction of the Employee Stock Ownership Plan, Matters Relating to Stock Units and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Prior RSU Award

April 15, 2026
Nxera Pharma’s QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia

April 14, 2026
Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia

April 12, 2026
Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases

April 8, 2026
Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly

March 31, 2026
Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals

March 5, 2026
Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea

March 4, 2026
Nxera Pharma Proposes Changes to its Board of Directors

February 13, 2026
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025

February 13, 2026
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals

February 12, 2026